362 related articles for article (PubMed ID: 35126377)
1. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.
Jin Y; Hou C; Li Y; Zheng K; Wang C
Front Immunol; 2021; 12():821538. PubMed ID: 35126377
[TBL] [Abstract][Full Text] [Related]
2. From mRNA sensing to vaccines.
Fauci AS; Merad M; Swaminathan S; Hur S; Topol E; Fitzgerald K; Reis e Sousa C; Corbett KS; Bauer S
Immunity; 2021 Dec; 54(12):2676-2680. PubMed ID: 34739870
[TBL] [Abstract][Full Text] [Related]
3. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
5. The variants of SARS-CoV-2 and the challenges of vaccines.
Han X; Ye Q
J Med Virol; 2022 Apr; 94(4):1366-1372. PubMed ID: 34890492
[TBL] [Abstract][Full Text] [Related]
6. A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.
Jawalagatti V; Kirthika P; Hewawaduge C; Park JY; Yang MS; Oh B; So MY; Kim B; Lee JH
Front Immunol; 2022; 13():811802. PubMed ID: 35250985
[TBL] [Abstract][Full Text] [Related]
7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
8. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.
Darling TL; Ying B; Whitener B; VanBlargan LA; Bricker TL; Liang CY; Joshi A; Bamunuarachchi G; Seehra K; Schmitz AJ; Halfmann PJ; Kawaoka Y; Elbashir SM; Edwards DK; Thackray LB; Diamond MS; Boon ACM
Med; 2022 May; 3(5):309-324.e6. PubMed ID: 35584653
[TBL] [Abstract][Full Text] [Related]
9. DNA Vaccines Expressing the Envelope and Membrane Proteins Provide Partial Protection Against SARS-CoV-2 in Mice.
Chen J; Deng Y; Huang B; Han D; Wang W; Huang M; Zhai C; Zhao Z; Yang R; Zhao Y; Wang W; Zhai D; Tan W
Front Immunol; 2022; 13():827605. PubMed ID: 35281016
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
[TBL] [Abstract][Full Text] [Related]
11. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
[TBL] [Abstract][Full Text] [Related]
12. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.
Begum J; Mir NA; Dev K; Buyamayum B; Wani MY; Raza M
Transbound Emerg Dis; 2021 May; 68(3):1111-1124. PubMed ID: 32815655
[TBL] [Abstract][Full Text] [Related]
13. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Coronavirus Vaccines against Syndrome Coronavirus 2 (SARS-CoV-2) and Its New Variants.
Abdi Ghavidel A; Rojhannezhad M; Kazemi B; Bandehpour M
Iran J Allergy Asthma Immunol; 2021 Dec; 20(6):647-671. PubMed ID: 34920649
[TBL] [Abstract][Full Text] [Related]
15. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses.
Alameh MG; Tombácz I; Bettini E; Lederer K; Sittplangkoon C; Wilmore JR; Gaudette BT; Soliman OY; Pine M; Hicks P; Manzoni TB; Knox JJ; Johnson JL; Laczkó D; Muramatsu H; Davis B; Meng W; Rosenfeld AM; Strohmeier S; Lin PJC; Mui BL; Tam YK; Karikó K; Jacquet A; Krammer F; Bates P; Cancro MP; Weissman D; Luning Prak ET; Allman D; Locci M; Pardi N
Immunity; 2021 Dec; 54(12):2877-2892.e7. PubMed ID: 34852217
[TBL] [Abstract][Full Text] [Related]
16. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
Wu K; Choi A; Koch M; Elbashir S; Ma L; Lee D; Woods A; Henry C; Palandjian C; Hill A; Jani H; Quinones J; Nunna N; O'Connell S; McDermott AB; Falcone S; Narayanan E; Colpitts T; Bennett H; Corbett KS; Seder R; Graham BS; Stewart-Jones GBE; Carfi A; Edwards DK
Vaccine; 2021 Dec; 39(51):7394-7400. PubMed ID: 34815117
[TBL] [Abstract][Full Text] [Related]
17. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
Tauzin A; Gong SY; Beaudoin-Bussières G; Vézina D; Gasser R; Nault L; Marchitto L; Benlarbi M; Chatterjee D; Nayrac M; Laumaea A; Prévost J; Boutin M; Sannier G; Nicolas A; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Bo Y; Perreault J; Gokool L; Morrisseau C; Arlotto P; Bazin R; Dubé M; De Serres G; Brousseau N; Richard J; Rovito R; Côté M; Tremblay C; Marchetti GC; Duerr R; Martel-Laferrière V; Kaufmann DE; Finzi A
Cell Host Microbe; 2022 Jan; 30(1):97-109.e5. PubMed ID: 34953513
[TBL] [Abstract][Full Text] [Related]
18. A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques.
O'Connor MA; Erasmus JH; Randall S; Archer J; Lewis TB; Brown B; Fredericks M; Groenier S; Iwayama N; Ahrens C; Garrison W; Wangari S; Guerriero KA; Fuller DH
Front Immunol; 2021; 12():800723. PubMed ID: 34992610
[TBL] [Abstract][Full Text] [Related]
19. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.
Abdullahi IN; Emeribe AU; Adekola HA; Abubakar SD; Dangana A; Shuwa HA; Nwoba ST; Mustapha JO; Haruna MT; Olowookere KA; Animasaun OS; Ugwu CE; Onoja SO; Gadama AS; Mohammed M; Daneji IM; Amadu DO; Ghamba PE; Onukegbe NB; Shehu MS; Isomah C; Babayo A; Ahmad AE
Hum Vaccin Immunother; 2021 Mar; 17(3):620-637. PubMed ID: 32936732
[TBL] [Abstract][Full Text] [Related]
20. Advances in the design and development of SARS-CoV-2 vaccines.
Peng XL; Cheng JS; Gong HL; Yuan MD; Zhao XH; Li Z; Wei DX
Mil Med Res; 2021 Dec; 8(1):67. PubMed ID: 34911569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
